234 related articles for article (PubMed ID: 32048727)
21. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
[TBL] [Abstract][Full Text] [Related]
22. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
Salman A; Ergun T; Gimenez-Arnau AM
J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
[No Abstract] [Full Text] [Related]
23. Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria.
Boyvadoglu C; Ulusal H; Taysı S; Ozaydin-Yavuz G; Yavuz IH; Korkmaz P; Inaloz HS
Mediators Inflamm; 2023; 2023():8087274. PubMed ID: 37795408
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
[TBL] [Abstract][Full Text] [Related]
25. Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real-life data.
Salman A; Aktas M; Apti Sengun O
Australas J Dermatol; 2021 Aug; 62(3):398-402. PubMed ID: 34156714
[TBL] [Abstract][Full Text] [Related]
26. Factors related to omalizumab resistance in chronic spontaneous urticaria.
Magen E; Chikovani T; Waitman DA; Kahan NR
Allergy Asthma Proc; 2019 Jul; 40(4):273-278. PubMed ID: 31262381
[No Abstract] [Full Text] [Related]
27. Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress.
Giménez-Arnau AM; Salman A
Drugs; 2020 Nov; 80(16):1617-1634. PubMed ID: 32857360
[TBL] [Abstract][Full Text] [Related]
28. Time-Dependent Effects in Chronic Urticaria: A Time-Series Perspective of Omalizumab Treatment.
Tagka A; Lambrou GI; Makris M; Nakou E; Nicolaidou E; Chatziioannou A; Katsarou A
Endocr Metab Immune Disord Drug Targets; 2020; 20(10):1726-1739. PubMed ID: 32167432
[TBL] [Abstract][Full Text] [Related]
29. How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers.
Türk M; Carneiro-Leão L; Kolkhir P; Bonnekoh H; Buttgereit T; Maurer M
J Allergy Clin Immunol Pract; 2020 Jan; 8(1):113-124. PubMed ID: 31374358
[TBL] [Abstract][Full Text] [Related]
30. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
31. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria.
Bae Y; Kang SH; Park JO; Park GH; Choi JH
Allergol Int; 2020 Apr; 69(2):304-306. PubMed ID: 31767272
[No Abstract] [Full Text] [Related]
32. Omalizumab in severe chronic urticaria: are slow and non-responders different?
Asero R
Eur Ann Allergy Clin Immunol; 2021 Nov; 53(6):263-266. PubMed ID: 32914943
[No Abstract] [Full Text] [Related]
33. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.
Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M
Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715
[No Abstract] [Full Text] [Related]
34. Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study.
Metz M; Torene R; Kaiser S; Beste MT; Staubach P; Bauer A; Brehler R; Gericke J; Letzkus M; Hartmann N; Erpenbeck VJ; Maurer M
Allergy; 2019 Jan; 74(1):141-151. PubMed ID: 29974963
[TBL] [Abstract][Full Text] [Related]
35. Are currently available biomarkers useful to discriminate CSU patients not controlled by low dose omalizumab maintenance therapy?
Asero R
Eur Ann Allergy Clin Immunol; 2020 Nov; 52(6):268-270. PubMed ID: 32191021
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
Giménez Arnau AM; Valero Santiago A; Bartra Tomás J; Jáuregui Presa I; Labrador Horrillo M; Miquel Miquel FJ; Ortiz de Frutos J; Sastre J; Silvestre Salvador JF; Ferrer Puga M
J Investig Allergol Clin Immunol; 2019; 29(5):338-348. PubMed ID: 30222111
[TBL] [Abstract][Full Text] [Related]
37. The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria.
Salman A; Comert E
J Cutan Med Surg; 2019; 23(5):496-500. PubMed ID: 31030540
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers of chronic spontaneous urticaria and their clinical implications.
Asero R; Cugno M
Expert Rev Clin Immunol; 2021 Mar; 17(3):247-254. PubMed ID: 33496195
[No Abstract] [Full Text] [Related]
39. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
40. The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria.
Acer E; Kaya Erdogan H; Yüksel Çanakçı N; Saracoglu ZN
Cutan Ocul Toxicol; 2019 Mar; 38(1):5-8. PubMed ID: 29969297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
